A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Hoffmann-La Roche
Arvinas Inc.
Myeloid Therapeutics
xCures
DualityBio Inc.
Seagen Inc.
Tango Therapeutics, Inc.
Tango Therapeutics, Inc.
Alaunos Therapeutics
Massive Bio, Inc.
Actym Therapeutics, Inc.
Merck Sharp & Dohme LLC
Travera Inc
Elicio Therapeutics
TCR2 Therapeutics
TCR2 Therapeutics
Alaunos Therapeutics
Alaunos Therapeutics
Telix Pharmaceuticals (Innovations) Pty Limited
NextPoint Therapeutics, Inc.
TransThera Sciences (Nanjing), Inc.
Merus B.V.
Janssen Research & Development, LLC
Elevation Oncology
Singlera Genomics Inc.
Zymeworks BC Inc.
Symphogen A/S
ABM Therapeutics Shanghai Company Limited
Travera Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Convalife (Shanghai) Co., Ltd.
ABM Therapeutics Corporation
TransThera Sciences (Nanjing), Inc.
Beijing Kejing Biotechnology Co., Ltd.
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
NextCure, Inc.
Chongqing Precision Biotech Co., Ltd
Chongqing Precision Biotech Co., Ltd
Hoffmann-La Roche
Klus Pharma Inc.
Tempest Therapeutics
Xencor, Inc.
Quadriga Biosciences, Inc.
Xencor, Inc.
Wellmarker Bio
Bayer
AbbVie